Newcells Biotech (“Newcells”), a number one drug discovery companion specializing within the growth of in vitro fashions and bespoke assay companies to enhance the prediction of in vivo human outcomes, right this moment introduced the launch of its imaging suite and superior lung Fibroblast-to-Myofibroblast Transition (FMT) assay. Comprising high-content and high-throughput tools, the state-of-the-art imaging suite augments the Firm’s service choices to supply extra in-depth and strong in vitro information. Newcells has developed a sequence of assays to leverage these capabilities; enabling researchers to speed up programmes with extra confidence on the consequences and localization of medicine in vivo.
Picture Credit score: Newcells Biotech
Newcells presents a variety of physiologically-relevant and functionally-validated iPSC and primary-cell fashions to help drug builders de-risk pre-clinical decision-making and enhance scientific translation. The brand new suite contains state-of-the-art imaging capabilities for Newcells’ in vitro retina, kidney and lung fashions, now with the addition of the superior lung FMT assay. It options imaging methods to maximise information era and evaluation throughout respective utility areas; an ImageXpress® Confocal HT.ai Excessive-Content material Imaging System to allow high-content imaging and extremely multiplexed assays, a ZEISS Axio Observer system with Apotome 3 for imaging of a number of pattern codecs, and an ImageXpress Pico Automated Cell Imaging System for a variety of assays.
The superior high-throughput high-sensitivity lung FMT assay facilitates customisable and fast evaluation of the efficacy of anti-fibrotic drug candidates. Constructing on the success of Newcells’ current FMT assay, the superior model gives information at higher-resolution, with simultaneous evaluation of 4 separate information outputs for extra correct choice and predictivity of drug results on pulmonary fibrosis. By using superior imaging and quantification know-how, the assay enhances understanding of a compound’s in vitro results, and can be utilized to raised inform the development of growth programmes.
The launch of our new imaging suite and enhanced fibrotic illness screening assay is a key step in our technique to supply modern, market-leading in vitro fashions that advance the invention and protected growth of recent medicine. We’re dedicated to steady innovation of our options to stay on the cutting-edge and greatest help our prospects’ analysis wants.”
Dr Mike Nicholds, CEO and Co-Founder, Newcells Biotech
He continued: “Because the capabilities of analytical know-how in imaging and omics accelerates, we are able to see alternatives to additional add worth to our prospects by making use of these methods to supply mechanistic information on how modern new therapies will have an effect on human tissues and organs. This current funding in imaging provides prospects the choice to assemble priceless data to help discovery and the interpretation to scientific trials”
